Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Vtesse
910 Clopper Road, Suite 220S
Gaithersburg, MD 20878
Phone: 240-801-9261
http://www.vtessepharma.com/

Vtesse, Inc. is a rare disease company dedicated to developing drugs for patients suffering from diseases that are underserved. The first spin-out company from Cydan Development, Inc., an orphan-drug accelerator that identifies and de-risks programs with therapeutic and commercial potential, Vtesse is working collaboratively with the NIH to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. Vtesse is led by a highly experienced management team that has been involved in the development of more than 20 approved drugs and vaccines. Its experienced consortium of investors, led by New Enterprise Associates, has committed initial funding that is expected to bring this compound through pivotal clinical trials.

Key Contact
Name
Ben Machielse
Title
CEO
Funding Events

Date
Amount
Type
Investors
Valuation
01/07/15 $25,000,000 Series A Alexandria Real Estate Equities
Bay City Capital
Lundbeckfond Ventures
Pfizer Strategic Investments Group
undisclosed
07/25/16 $17,000,000 Series A Extension Alexandria Real Estate Equities
Bay City Capital
Lundbeckfond Ventures
Pfizer Venture Investments
undisclosed